AURA BIOSCIENCES

Aura Biosciences reports positive Phase 2 data for bel-sar in early-stage choroidal melanoma and Phase 1 data in NMIBC, with ongoing Phase 3 CoMpass trial in Europe. The company plans to expand bel-sar's development to metastases in the choroid and ocular surface cancers, with a strong cash position to support operations into 2H 2026.

Single-dose belzupacap sarotalocan (bel-sar; AU-011) showed promising activity and safety in non–muscle-invasive bladder cancer (NMIBC) patients in a phase 1 trial. 4/5 low-grade NMIBC patients achieved complete clinical response with bel-sar and light activation. No grade 2/3 adverse events reported. Aura Biosciences plans to expand the trial to optimize dose and regimen, aiming for a phase 2 trial.

Aura Biosciences announced positive phase 2 results for bel-sar (AU-011) in treating early-stage choroidal melanoma, showing 80% tumour control and 90% vision preservation with a favourable safety profile.

Aura Biosciences announced positive Phase 2 results for bel-sar (AU-011) in treating early-stage choroidal melanoma, showing 80% tumor control and 90% visual acuity preservation with a favorable safety profile, presented at The Retina Society Annual Meeting in Lisbon.

Aura Biosciences' new therapy, bel-sar, for early-stage choroidal melanoma shows promise in Phase II trials, potentially offering a vision-preserving alternative to radiation therapy. The treatment uses virus-drug conjugates activated by light to target tumors, with results indicating high efficacy and safety. Aura plans to advance to Phase III trials and explore broader cancer applications.

Clearside Biomedical discussed its Q4 2023 financial results and corporate updates, highlighting progress in its CLS-AX clinical development program for wet AMD, including the initiation and completion of the Phase IIb trial, Odyssey. The company emphasized its leadership in suprachoroidal drug delivery technology, collaborations, and anticipated data readouts in 2024. Financial updates included a cash balance sufficient to fund operations into Q3 2025.

Integrin αvβ6 plays a crucial role in cell adhesion, migration, and signaling, with significant implications in cancer progression and epithelial-mesenchymal transition (EMT). Its up-regulation is linked to poor prognosis in various cancers, making it a potential target for cancer treatment. Research focuses on its biology, role in healthy humans, and therapeutic targeting strategies, including imaging and drug delivery approaches.